Suvorexant (Belsomra): Dosing, Comparisons, and What to Expect

What Is Suvorexant and How Does It Work?

Suvorexant works by blocking orexin receptors rather than broadly sedating the brain. Orexin (also called hypocretin) is a neuropeptide that actively keeps you awake. By occupying both OX1R and OX2R receptors, suvorexant quiets the wake-promoting signal without globally depressing the central nervous system, which is the mechanism that makes older sleep drugs prone to next-day sedation, respiratory suppression, and dependence.

The orexin system was identified partly through research into narcolepsy, a condition caused by the loss of orexin-producing neurons. That discovery, summarized in the foundational work by Chemelli et al. published in Cell, showed that animals without orexin signaling fall asleep involuntarily during active waking periods. [1] Blocking those same receptors pharmacologically creates a controlled, reversible version of that effect at bedtime.

Suvorexant received FDA approval on August 13, 2014, making it the first orexin receptor antagonist approved for insomnia in the United States. [2] The FDA-approved label covers adults with difficulty falling asleep or staying asleep. The drug is classified as DEA Schedule IV, the same schedule as benzodiazepines, though its abuse-potential profile differs mechanistically from GABAergic agents. [2]

The roughly 12-hour half-life means the drug is largely cleared by morning in most patients, though next-day drowsiness remains a documented adverse effect at higher doses. Patients with hepatic impairment clear the drug more slowly, and the prescribing label advises caution in moderate hepatic impairment and avoidance in severe impairment. [2]

FDA-Approved Dosing and Administration

The recommended starting dose is 10 mg taken no more than 30 minutes before bed, with at least 7 hours remaining before the planned wake time. If 10 mg is well tolerated but insufficiently effective, the dose may be increased to 20 mg. [2] No dose above 20 mg is approved. The FDA specifically rejected the manufacturer's original application for a 40 mg dose after the advisory committee raised concerns about next-morning impairment. [3]

Take with food or without. High-fat meals delay peak plasma concentration by about 1.5 hours, so patients who want faster onset should take the drug on an empty stomach or after a light snack. [2]

Strong CYP3A inhibitors (such as ketoconazole or clarithromycin) dramatically increase suvorexant exposure. The maximum dose is 10 mg when used concurrently with a strong CYP3A inhibitor. [2] Moderate CYP3A inhibitors (such as diltiazem or fluconazole) warrant a starting dose of 5 mg, though 5 mg is not a commercially available tablet strength, so clinicians often avoid the combination or switch medications. [2]

Patients taking CNS depressants, including alcohol, opioids, or benzodiazepines, face additive sedation risk and should discuss this explicitly with their prescriber before starting suvorexant.

Phase 3 Clinical Trial Data

The key Phase 3 program for suvorexant enrolled 1,021 adults (18 to 64 years) and 285 older adults (65 years and older) in two randomized, double-blind, placebo-controlled trials. [4] The primary endpoints were subjective total sleep time (sTST) and subjective time to sleep onset (sTSO) at 1 month and 3 months.

At 3 months, suvorexant 15/20 mg (younger adults received 20 mg; older adults received 15 mg because of pharmacokinetic differences) reduced wake time after sleep onset by approximately 28 minutes compared with placebo and cut time to sleep onset by roughly 9 minutes versus placebo, both reaching statistical significance (P<0.001). [4] Objective polysomnographic data collected in a subset confirmed these self-reported gains: suvorexant reduced latency to persistent sleep and improved total sleep time on PSG. [4]

A separate 1-year safety study, also published in the trial package reviewed by the FDA, showed that suvorexant did not produce significant rebound insomnia or withdrawal symptoms upon abrupt discontinuation at doses used in the key trials. [4] That finding distinguishes it from benzodiazepines, which commonly produce rebound insomnia after abrupt cessation.

The phase 3 data also showed that next-day somnolence affected approximately 7% of patients on the 20 mg dose versus 3% on placebo. [4] Suicidal ideation and sleep paralysis were listed as rare but serious adverse events warranting monitoring, consistent with class-level concerns about drugs that affect sleep architecture. [2]

Suvorexant vs. Zolpidem (Ambien)

Zolpidem is a positive allosteric modulator of GABA-A receptors, approved in 1992, and remains the most prescribed sleep medication in the United States. [5] Its mechanism produces rapid sedation but also respiratory depression, psychomotor impairment, and, in some patients, complex sleep behaviors such as sleepwalking or sleep-driving. [5]

A 2019 head-to-head randomized trial published in The Lancet Neurology compared suvorexant 20 mg with zolpidem 10 mg over 4 weeks in 291 patients with primary insomnia. [6] Suvorexant was noninferior to zolpidem for sleep onset latency and superior for wake time after sleep onset (P<0.05). [6] Next-morning residual sedation scores were comparable between arms in that trial, though the FDA label for zolpidem carries a specific warning about next-morning impairment in women (who clear the drug 45% more slowly than men), prompting the FDA in 2013 to halve the recommended dose in women to 5 mg immediate-release. [5]

Zolpidem carries a boxed warning added in 2023 covering serious injuries and deaths from complex sleep behaviors, including sleep-driving. [5] Suvorexant's label does not carry a boxed warning, though sleep paralysis and hypnagogic hallucinations are noted as adverse events. [2]

Clinicians often consider suvorexant for patients who cannot tolerate zolpidem, who have a history of substance use disorder (where GABA potentiating drugs carry higher misuse risk), or who have obstructive sleep apnea, given that suvorexant does not suppress respiratory drive the way GABAergic agents do. A 2020 study in patients with mild-to-moderate OSA found suvorexant 10 mg did not worsen the apnea-hypopnea index. [7]

Suvorexant vs. Eszopiclone (Lunesta)

Eszopiclone is a cyclopyrrolone non-benzodiazepine hypnotic that also acts on GABA-A receptors. [8] It is notable for its approval for long-term use (the FDA label does not specify a duration limit, unlike most sleep drugs), and a 6-month randomized controlled trial published in Sleep demonstrated sustained efficacy without tolerance development. [8]

The main patient complaint with eszopiclone is a metallic or bitter taste, reported by 17 to 34% of participants in clinical trials depending on dose. [8] Suvorexant does not carry this adverse effect. Both drugs are Schedule IV and share residual sedation risk, though eszopiclone has a shorter half-life of approximately 6 hours (compared with suvorexant's 12 hours), meaning morning clearance is faster for most patients. For patients who struggle primarily with sleep onset rather than sleep maintenance, eszopiclone 1 mg or 2 mg may be sufficient with less next-day carry-over. For patients with prominent sleep-maintenance insomnia, suvorexant's longer duration may be an advantage. [2][8]

Suvorexant vs. Zaleplon (Sonata)

Zaleplon has the shortest half-life of the common prescription sleep aids, approximately 1 hour. [9] That rapid elimination makes it uniquely suited for patients who wake in the middle of the night and need help returning to sleep, provided they have at least 4 hours before they must wake. [9] Taking zaleplon at 2 AM with a 6 AM alarm is clinically reasonable in a way that suvorexant is not, given suvorexant's 12-hour half-life.

Zaleplon is also a GABA-A modulator, shares the CNS-depressant adverse effect profile of zolpidem and eszopiclone, and carries comparable abuse potential for the Schedule IV class. [9] Patients with a primary complaint of sleep-onset insomnia and no significant sleep-maintenance insomnia are reasonable candidates for zaleplon. Patients with both onset and maintenance problems are better matched to suvorexant or eszopiclone. [9]

Suvorexant vs. Melatonin

Melatonin is an endogenous hormone produced by the pineal gland in response to darkness, and its exogenous supplement form is available over the counter in the United States without a prescription. [10] It acts on MT1 and MT2 receptors to shift circadian timing and modestly promote sleep onset in circadian-rhythm disorders such as jet lag and delayed sleep-wake phase disorder. [10]

A meta-analysis of 19 randomized trials published in PLOS ONE (N=1,683 total participants) found that exogenous melatonin reduced sleep onset latency by a mean of 7.06 minutes and increased total sleep time by 8.25 minutes compared with placebo, effects that are statistically significant but modest in magnitude. [11] By comparison, suvorexant 20 mg reduced sleep onset latency by roughly 9 minutes and wake after sleep onset by 28 minutes in its key trials. [4]

Melatonin doses used in clinical practice vary widely. The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline on pharmacologic treatment of chronic insomnia states: "We suggest that clinicians not use melatonin as a treatment for sleep onset or sleep maintenance insomnia disorder." [12] That recommendation carries a weak strength of evidence grade, acknowledging that melatonin may still help in circadian disorders, shift-work disorder, and jet lag. [12]

For patients who prefer to avoid controlled substances, melatonin 0.5 mg to 3 mg taken 30 to 60 minutes before a desired bedtime remains a low-risk first step, particularly for circadian phase issues. For patients with diagnosable chronic insomnia disorder, the evidence supports prescription options including suvorexant more strongly than melatonin. [12]

AASM Guidelines and Where Suvorexant Fits

The AASM 2017 clinical practice guideline on chronic insomnia, published in the Journal of Clinical Sleep Medicine, is the primary guideline document governing pharmacologic prescribing in the United States. [12] The guideline provides specific recommendations for suvorexant.

The guideline states: "We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment)." [12] This is a weak recommendation based on low-quality evidence, reflecting the fact that large-scale comparative effectiveness data across drug classes were unavailable at the time of publication.

A structured prescribing framework helps clinicians and patients select among the major options based on insomnia subtype:

Sleep-onset only, short-term: Zaleplon 5 to 10 mg or zolpidem immediate-release 5 mg (women) / 10 mg (men), with a plan to reassess after 2 to 4 weeks. [2][9]

Sleep maintenance, or both onset and maintenance, longer course: Suvorexant 10 to 20 mg or eszopiclone 2 to 3 mg, which both have evidence for sustained use beyond 4 weeks. [2][8]

Circadian-phase shift or jet lag: Melatonin 0.5 mg to 3 mg, timed to the target time zone, not primarily as a hypnotic. [10][12]

Substance use disorder history or OSA: Suvorexant preferred over GABAergic agents because of the non-GABAergic mechanism and absence of respiratory suppression. [7]

Cognitive behavioral therapy for insomnia (CBT-I) carries a strong recommendation as first-line therapy in the AASM guideline and should be offered before or alongside any pharmacologic option. [12] Digital CBT-I programs have demonstrated efficacy in randomized trials including the SHUT-I trial, reducing insomnia severity index scores by 6.6 points more than control at 8 weeks. [13]

Safety, Adverse Effects, and Monitoring

The most frequently reported adverse event in suvorexant trials is somnolence, affecting roughly 7% of patients on 20 mg. [4] Less common events include headache (approximately 6%), dizziness (approximately 3%), and abnormal dreams (approximately 2%). [4]

Sleep paralysis, a transient inability to move or speak while waking or falling asleep, was reported in 0.25% of patients on suvorexant across clinical trials versus 0% on placebo. [2] Hypnagogic and hypnopompic hallucinations occurred in approximately 1.4% of suvorexant-treated patients. [2] Both phenomena are consistent with the drug's mechanism of action, given that orexin normally suppresses REM atonia during waking.

Worsening depression and suicidal ideation were observed at low rates across sleep-medication trials including suvorexant's development program. The FDA requires monitoring for these events across the class. [2] Patients with a current major depressive episode should have their depression managed concurrently, and clinicians should ask about suicidal ideation at follow-up visits.

Driving impairment. A randomized, double-blind, crossover study using a driving simulator found that suvorexant 20 mg taken at 11 PM produced impaired driving performance at 8 hours post-dose in some subjects compared with placebo (P<0.05). [14] Patients should be counseled not to drive or operate heavy machinery the morning after taking suvorexant until they know how the drug affects them individually.

No dose adjustment is required for mild or moderate renal impairment. Avoid suvorexant in severe hepatic impairment. [2]

Special Populations

Older adults. The Phase 3 trials used a dose cap of 15 mg in adults aged 65 and older because pharmacokinetic modeling showed higher peak exposures in this group. [4] Falls and fall-related injuries represent a particular concern in older patients taking any hypnotic. A prospective cohort study of 139,900 Medicare beneficiaries found that benzodiazepine receptor agonists were associated with a 34% increased risk of hip fracture. [15] Suvorexant's fall-risk data in older adults are less extensive, but patients and caregivers should still be counseled about nighttime ambulation safety. [4]

Pregnancy. Suvorexant is Pregnancy Category C. Animal studies showed developmental toxicity at exposures exceeding the human therapeutic range. No adequate human studies exist. [2] Use only if the potential benefit justifies the potential risk.

Pediatrics. Safety and efficacy have not been established in patients under 18 years. Suvorexant is not approved for pediatric use. [2]

Cost, Access, and Generic Availability

Belsomra (branded suvorexant) has been available since 2015. Generic suvorexant entered the U.S. market in 2023 following patent litigation, substantially reducing out-of-pocket cost. [2] As of early 2025, generic suvorexant 10 mg and 20 mg tablets are manufactured by multiple generic companies.

Cash prices for generic suvorexant vary by pharmacy but are generally lower than branded Belsomra. Patients should use a pharmacy discount card (GoodRx or similar) and confirm their insurance tier before filling the prescription. Prior authorization requirements vary by payer but are common, particularly for patients who have not previously tried a generic hypnotic such as generic zolpidem.

The branded 30-count Belsomra pack retails for roughly $400 to $450 without insurance. [2] Generic versions are available for substantially less. Patients who cannot afford the medication should ask their prescriber about the Merck patient assistance program, which the manufacturer offers for income-qualifying patients.